Key result
Anti-IL-1 drugs and modulation of intestinal microbiota represent potential biotechnological approaches for the prevention of cardiovascular diseases driven by chronic inflammation.
Answers are grounded in this paper and cite their sources.
This review highlights the role of interleukin-1 in cardiovascular disease progression and discusses potential therapeutic strategies including anti-IL-1 drugs and microbiota modulation.
Cardiovascular diseases (CVD) are the leading cause of death and disability worldwide. Low-grade chronic inflammation plays a major role in the progression of CVD. The review examines the role of interleukin-1 (IL-1) family cytokines in the development of CVD. IL-1 family cytokines play an important role in the progression of atherosclerosis, the development of myocardial infarction (MI), and chronic heart failure (CHF). The review presents data on the mechanisms of IL-1 action and the effectiveness of anti-IL-1 drugs in the prevention of CVD. Also, in this review, we consider the possibility of using changes in the composition of intestinal microbiota as a method of influencing the level of IL-1.
No takes yet. Share an insight, caveat, or question.
Protsak et al. (2025) conducted a review in Cardiovascular diseases. Anti-IL-1 drugs and intestinal microbiota modulation was evaluated. Anti-IL-1 drugs and modulation of intestinal microbiota represent potential biotechnological approaches for the prevention of cardiovascular diseases driven by chronic inflammation.
Synapse has enriched 10 related papers. Consider them for comparative context: